Anti-Inflammatory Effects of Lysozyme Against HMGB1 in Human Endothelial Cells and in Mice
- 22 April 2015
- journal article
- Published by Springer Nature in Inflammation
- Vol. 38 (5) , 1911-1924
Abstract
High mobility group box 1 (HMGB1) was recently shown to be an important extracellular mediator of severe vascular inflammatory disease, sepsis. Lysozyme protects us from the ever-present danger of bacterial infection and binds to bacterial lipopolysaccharide (LPS) with a high affinity. Here, we show, for the first time, the anti-septic effects of lysozyme in HMGB1-mediated inflammatory responses in vitro and in vivo. The data showed that lysozyme posttreatment suppressed LPS-mediated release of HMGB1 and HMGB1-mediated cytoskeletal rearrangement. Lysozyme also inhibited HMGB1-mediated hyperpermeability and leukocyte migration in human endothelial cells. In addition, lysozyme inhibited the HMGB1-mediated activation of Akt, nuclear factor-κB (NF-κB), extracellular regulated kinases (ERK) 1/2 and production of interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α), and chemoattractant protein-1 (MCP-1) in HUVECs. Furthermore, lysozyme reduced the cecal ligation and puncture (CLP)-induced release of HMGB1, migration of leukocytes, septic mortality, and pulmonary damage in mice. Collectively, these results suggest lysozyme as a candidate therapeutic agent for the treatment of vascular inflammatory diseases via inhibition of the HMGB1 signaling pathway.Keywords
This publication has 62 references indexed in Scilit:
- High Mobility Group Box-1 Promotes the Proliferation and Migration of Hepatic Stellate Cells via TLR4-Dependent Signal Pathways of PI3K/Akt and JNKPLOS ONE, 2013
- Emodin-6-O-β-d-glucoside down-regulates endothelial protein C receptor sheddingArchives of Pharmacal Research, 2013
- Inhibitory effects of epi-sesamin on HMGB1-induced vascular barrier disruptive responses in vitro and in vivoToxicology and Applied Pharmacology, 2013
- Polyphosphate elicits pro‐inflammatory responses that are counteracted by activated protein C in both cellular and animal modelsJournal of Thrombosis and Haemostasis, 2012
- Activated protein C inhibits high mobility group box 1 signaling in endothelial cellsBlood, 2011
- HMGB1 Is a Therapeutic Target for Sterile Inflammation and InfectionAnnual Review of Immunology, 2011
- HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruptionMicrovascular Research, 2011
- Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking TalePhysiological Reviews, 2010
- Immunodesign of experimental sepsis by cecal ligation and punctureNature Protocols, 2008
- The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cellsBlood, 2007